- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Marksans Pharma Ltd (MARK)
Marksans Pharma Ltd stock price live, this page displays NSE MARK stock exchange data. View the MARK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Marksans Pharma Ltd real time stock price chart below.
What Is the Marksans Pharma Ltd Stock Price Today?
The Marksans Pharma Ltd stock price today is 330.45.
What Is the Stock Symbol for Marksans Pharma Ltd?
The stock symbol for Marksans Pharma Ltd is "MARK."
What Stock Exchange Does Marksans Pharma Ltd Trade On?
Marksans Pharma Ltd is listed and trades on the NSE stock exchange.
Is Marksans Pharma Ltd a Good Stock to Buy?
Determining whether Marksans Pharma Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MARK quote. (ISIN: INE750C01026)
What Is the Marksans Pharma Ltd Stock Price Today?
The Marksans Pharma Ltd stock price today is 330.45.
What Is the Stock Symbol for Marksans Pharma Ltd?
The stock symbol for Marksans Pharma Ltd is "MARK."
What Stock Exchange Does Marksans Pharma Ltd Trade On?
Marksans Pharma Ltd is listed and trades on the NSE stock exchange.
Is Marksans Pharma Ltd a Good Stock to Buy?
Determining whether Marksans Pharma Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MARK quote. (ISIN: INE750C01026)
330.45
-2.55(-0.77%)
Closed·
Fair Value
An estimate of a Marksans Pharma Ltd's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
325.45
345.50
52 wk Range
155.00
345.50
Unusual trading volume
1/3
Fair Value
An estimate of a Marksans Pharma Ltd's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
325.45345.50
52 wk Range
155.00345.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.27%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.27%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MARK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Marksans Pharma Ltd's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
324.33
Downside
-1.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Mankind Pharma shares get buy rating- Investing.com
- Mankind Pharma shares get buy rating
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 324.33
(-1.85% Downside)
Marksans Pharma Ltd Earnings Call Summary for Q1/2027
- Marksans Pharma Q1 FY27 revenue rose 35.6% YoY to INR 840.8 crores, but missed forecast of $8.88B by 4.28%; stock fell 3.07% to $303.
- EBITDA more than doubled to INR 213 crores (25.3% margin); PAT surged 173.9% to INR 159.4 crores, both quarterly records.
- Europe revenue jumped 74.7% YoY to INR 356 crores; cash balance exceeded INR 1,000 crores for first time, reaching INR 1,058 crores.
- FY27 guidance unchanged at 15-20% revenue growth, 20-21% EBITDA margin due to geopolitical uncertainty and cost pressures.
- Management expects Q3 to be strongest quarter; gross margin to normalize to 55-56% from 59.1% as inventory benefits fade.
Last Updated: 13/08/2026, 13:14
Read Full TranscriptEarnings
Latest Release
Aug 12, 2026
EPS / Forecast
3.45 / --
Revenue / Forecast
8.41B / 8.88B
Compare MARK to Peers and Sector
Metrics to compare | MARK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMARKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.2x | 30.5x | −0.4x | |
PEG Ratio | 0.62 | 0.34 | 0.00 | |
Price/Book | 5.0x | 3.3x | 2.6x | |
Price / LTM Sales | 4.8x | 3.7x | 3.1x | |
Upside (Analyst Target) | 13.5% | 7.7% | 47.9% | |
Fair Value Upside | Unlock | 0.7% | 6.3% | Unlock |
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Marksans Pharma Ltd (MARK) Stock Price Today?
The Marksans Pharma Ltd stock price today is 330.45 INR.
What Stock Exchange Does Marksans Pharma Ltd Trade On?
Marksans Pharma Ltd is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Marksans Pharma Ltd?
The stock symbol for Marksans Pharma Ltd is "MARK."
What Is the Marksans Pharma Ltd Market Cap?
As of today, Marksans Pharma Ltd market cap is 149.20B INR.
What Is Marksans Pharma Ltd's Earnings Per Share (TTM)?
The Marksans Pharma Ltd EPS (TTM) is 11.40.
When Is the Next Marksans Pharma Ltd Earnings Date?
Marksans Pharma Ltd will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is MARK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Marksans Pharma Ltd Stock Split?
Marksans Pharma Ltd has split 1 times.
How Many Employees Does Marksans Pharma Ltd Have?
Marksans Pharma Ltd has 1685 employees.
What is the current trading status of Marksans Pharma Ltd (MARK)?
As of Aug 17, 2026, Marksans Pharma Ltd (MARK) is trading at a price of 330.45 INR, with a previous close of 333.00 INR. The stock has fluctuated within a day range of 325.45 INR to 345.50 INR, while its 52-week range spans from 155.00 INR to 345.50 INR.
What Is Marksans Pharma Ltd (MARK) Price Target According to Analysts?
The average 12-month price target for Marksans Pharma Ltd is 324.33 INR, with a high estimate of 385 INR and a low estimate of 210 INR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -1.85% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.